8-K: Recursion Pharmaceuticals Acquires Full Rights to Potential First-in-Class Oral Therapy for Rare Genetic Disorder

Recursion Pharmaceuticals, Inc. has acquired full ownership of REV102, a potential first-in-class oral ENPP1 inhibitor for hypophosphatasia, from Rallybio Corporation, enhancing its pipeline with a promising preclinical asset.

Summary

• Recursion Pharmaceuticals, Inc. (the Company) has acquired the remaining 50% of the issued and outstanding membership interests of RE Ventures I, LLC (ENPP1 JV) from Rallybio Corporation, making ENPP1 JV an indirect wholly-owned subsidiary.
• The acquisition includes full rights to REV102, a potential first-in-class oral ENPP1 inhibitor, and an associated backup molecule for the treatment of hypophosphatasia (HPP), a rare and debilitating genetic disorder.
• As partial consideration, Recursion paid Rallybio 1,457,952 shares of its Class A common stock on July 8, 2025, calculated by dividing $7,500,000 by a per share price of $5.1442, which was the volume weighted average price over the seven trading days ending July 7, 2025.
• Additional contingent consideration includes a payment of $12,500,000 in shares upon the initiation of additional preclinical studies and a $5,000,000 cash milestone payment upon the initiation of dosing in a Phase 1 clinical study.
• Rallybio is also eligible to receive low single-digit royalties on all future net sales of the compound and potential payments if Recursion sells the REV102 program.
• The aggregate number of shares issued under the Purchase Agreement will not exceed 19.9% of the Company's outstanding Class A and Class B common stock, with any payments exceeding this limit to be made in cash.
• REV102 is currently in IND-enabling studies, with the initiation of Phase 1 clinical trials expected in the second half of 2026.
• The program targets ENPP1, an enzyme implicated in HPP, aiming to restore inorganic pyrophosphate (PPi) balance for proper bone mineralization, addressing the underlying cause of the disease.
• HPP affects over 7,800 diagnosed patients across the US and EU5, many of whom have limited access to current Enzyme Replacement Therapies (ERTs).

Sentiment

Score: 8

Explanation: The acquisition of full rights to a potential first-in-class oral therapy for a rare disease, coupled with the strategic advantages of an oral small molecule over existing injectable therapies, represents a significant positive development for Recursion's pipeline and long-term growth prospects, despite the asset being in preclinical stage.

Positives

• Acquisition of full ownership of REV102, a potential first-in-class oral disease-modifying therapy for Hypophosphatasia (HPP), significantly strengthens Recursion's pipeline.
• REV102 offers potential advantages over existing Enzyme Replacement Therapies (ERTs), including oral administration for convenience and improved patient quality of life.
• As a preliminarily non-immunogenic small molecule, REV102 could offer a safer profile compared to biological ERTs, which can sometimes induce immune responses.
• The program leverages the Recursion OS, an integrated AI/experimental platform, for precision design and optimization, demonstrating the platform's utility in drug discovery.
• Early preclinical data has shown a favorable safety profile in animal models and validated ENPP1 as a druggable target in later-onset HPP.

Negatives

• REV102 is currently a preclinical asset, meaning it is still in early development stages with a high risk of failure before reaching market.
• Contingent equity and cash payments are dependent on the achievement of specific preclinical and clinical milestones, which are not guaranteed.
• The acquisition involves the issuance of new Class A common stock, which could lead to dilution for existing shareholders.

Risks

• Challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors.
• Ability to leverage and enhance the drug discovery platform.
• Ability to obtain financing for development activities and other corporate purposes.
• Success of collaboration activities.
• Ability to obtain regulatory approval of, and ultimately commercialize, drug candidates.
• Ability to obtain, maintain, and enforce intellectual property protections.
• Cyberattacks or other disruptions to technology systems.
• Ability to attract, motivate, and retain key employees and manage growth.

Future Outlook

Recursion Pharmaceuticals expects to accelerate the development of REV102, aiming for it to become the first potential oral disease-modifying treatment for Hypophosphatasia (HPP). The company plans to leverage its integrated AI/experimental platform (Recursion OS) to gain deeper insights and expedite the delivery of this potential treatment. Initiation of Phase 1 clinical trials for REV102 is anticipated in the second half of 2026.

Management Comments

• David Hallett, Chief Scientific Officer of Recursion, stated: "Having full ownership of this important program allows Recursion to accelerate the development of the first potential oral disease-modifying treatment to HPP patients, who currently face significant challenges with limited access to existing therapies. While this is a preclinical asset that will require further study, we look forward to leveraging the full power of the Recursion OS to gain even deeper insights and accelerate delivery of the potential treatment."
• Stephen Uden, M.D., Chief Executive Officer of Rallybio, commented: "By combining Rallybio’s expertise in HPP preclinical and translational research with Recursion’s integrated AI/experimental platform, we transformed this concept into the first potential oral disease-modifying treatment for HPP. We look forward to the advancement of REV102 through key milestones and, ultimately, to the delivery of this important treatment to patients in need."

Industry Context

The acquisition of full rights to a promising preclinical asset for a rare genetic disorder like Hypophosphatasia (HPP) aligns with a broader industry trend where pharmaceutical companies seek to build specialized pipelines addressing high unmet medical needs. The focus on developing an oral disease-modifying therapy for HPP, a condition currently managed with injectable Enzyme Replacement Therapies (ERTs), reflects a strategic move towards more convenient and patient-friendly treatment modalities. Furthermore, Recursion's emphasis on leveraging its AI/experimental platform (Recursion OS) for drug design and optimization positions it within the growing 'TechBio' sector, where technology and artificial intelligence are increasingly integrated into drug discovery processes to accelerate development and improve candidate profiles.

Comparison to Industry Standards

• The acquisition of a preclinical asset with 'potential first-in-class oral disease-modifying' characteristics for a rare genetic disorder like HPP aligns with industry trends where companies seek to build specialized pipelines addressing high unmet medical needs, similar to how companies like Alexion Pharmaceuticals (now part of AstraZeneca) have focused on rare disease portfolios.
• The focus on an oral small molecule therapy for HPP, compared to existing Enzyme Replacement Therapies (ERTs) which are often injectable biologics (e.g., as seen with enzyme replacement therapies for lysosomal storage disorders), represents a significant potential advantage in patient convenience and quality of life, a common goal in drug development for chronic conditions.
• The use of an integrated AI/experimental platform (Recursion OS) for drug design and optimization is a leading-edge approach in the pharmaceutical industry, aiming to accelerate discovery and improve candidate profiles, differentiating Recursion from traditional drug development models and placing it among innovators like BenevolentAI or Exscientia.
• The deal structure, including upfront equity, contingent equity, milestone payments, and low single-digit royalties, is a standard model for licensing or acquisition of early-stage assets in the biotech sector, balancing risk and reward for both parties, comparable to numerous early-stage biotech licensing agreements.

Stakeholder Impact

• Shareholders: Potential for long-term value creation from a promising pipeline asset; potential for dilution from equity issuance (though capped).
• Patients (HPP): Potential for a more convenient, accessible, and potentially safer oral treatment option for a debilitating genetic disorder.
• Rallybio Corporation: Receives upfront equity, potential future equity/cash milestones, and low single-digit royalties on future net sales.
• Employees (Recursion): Enhanced pipeline and strategic focus, potentially leading to new development work and opportunities.

Next Steps

• Continue IND-enabling studies for REV102.
• Initiate additional preclinical studies for REV102, which would trigger a $12.5 million contingent equity payment.
• Initiate Phase 1 clinical trials for REV102, expected in the second half of 2026, which would trigger a $5 million milestone payment.
• File a registration statement with the SEC for the resale of the issued shares by Rallybio.

Key Dates

Recommendation

Keywords

Recursion Pharmaceuticals, Rallybio, REV102, ENPP1 inhibitor, Hypophosphatasia, HPP, rare disease, oral therapy, drug discovery, clinical stage, TechBio, genetic disorder, preclinical, IND-enabling studies, Phase 1 clinical trials, acquisition, equity, milestone payments, royalties, AI/ML drug discovery